Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Graphite Bio IncCommon Stock stock
Learn how to easily invest in Graphite Bio IncCommon Stock stock.
Graphite Bio Inc. Common Stock is a biotechnology business based in the US. Graphite Bio IncCommon Stock shares (GRPH) are listed on the NASDAQ and all prices are listed in US Dollars. Graphite Bio IncCommon Stock employs 57 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Graphite Bio IncCommon Stock
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GRPH – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Graphite Bio IncCommon Stock stock price (NASDAQ: GRPH)Use our graph to track the performance of GRPH stocks over time.
Graphite Bio IncCommon Stock shares at a glance
|Latest market close||$8.97|
|52-week range||$8.11 - $34.00|
|50-day moving average||$11.01|
|200-day moving average||$16.36|
|Wall St. target price||$33.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.05|
Buy Graphite Bio IncCommon Stock shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Graphite Bio IncCommon Stock stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Graphite Bio IncCommon Stock price performance over time
|1 week (2022-01-14)||-10.83%|
|1 month (2021-12-21)||-18.16%|
|3 months (2021-10-21)||-29.31%|
|6 months (2021-07-21)||-63.45%|
|1 year (2021-01-17)||N/A|
|2 years (2020-01-17)||N/A|
|3 years (2019-01-17)||N/A|
|5 years (2017-01-17)||N/A|
Graphite Bio IncCommon Stock financials
|Gross profit TTM||$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$503.5 million|
TTM: trailing 12 months
Graphite Bio IncCommon Stock share dividends
We're not expecting Graphite Bio IncCommon Stock to pay a dividend over the next 12 months.
Graphite Bio IncCommon Stock overview
Graphite Bio, Inc. , a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc. , and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc.
Graphite Bio IncCommon Stock in the news
Netflix quietly admits streaming competition is eating into growth
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Frequently asked questionsWhat percentage of Graphite Bio IncCommon Stock is owned by insiders or institutions?
Currently 9.514% of Graphite Bio IncCommon Stock shares are held by insiders and 86.931% by institutions. How many people work for Graphite Bio IncCommon Stock?
Latest data suggests 57 work at Graphite Bio IncCommon Stock. When does the fiscal year end for Graphite Bio IncCommon Stock?
Graphite Bio IncCommon Stock's fiscal year ends in December. Where is Graphite Bio IncCommon Stock based?
Graphite Bio IncCommon Stock's address is: 201 Haskins Way, South San Francisco, CA, United States, 94080 What is Graphite Bio IncCommon Stock's ISIN number?
Graphite Bio IncCommon Stock's international securities identification number is: US38870X1046
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert